[PDF][PDF] Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
HL Gomez, DC Doval, MA Chavez… - Journal of Clinical …, 2008 - researchgate.net
Journal of Clinical Oncology, 2008•researchgate.net
Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced
or Metastatic Breast Cancer Page 1 Efficacy and Safety of Lapatinib As First-Line Therapy for
ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer Henry L. Gomez, Dinesh C.
Doval, Miguel A. Chavez, Peter C.-S. Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra X.
Franco, Louis WC Chow, Michael C. Arbushites, Michelle A. Casey, Mark S. Berger, Steven H.
Stein, and George W. Sledge From the Instituto Nacional de Enfermedades Neoplásicas; …
or Metastatic Breast Cancer Page 1 Efficacy and Safety of Lapatinib As First-Line Therapy for
ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer Henry L. Gomez, Dinesh C.
Doval, Miguel A. Chavez, Peter C.-S. Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra X.
Franco, Louis WC Chow, Michael C. Arbushites, Michelle A. Casey, Mark S. Berger, Steven H.
Stein, and George W. Sledge From the Instituto Nacional de Enfermedades Neoplásicas; …
Purpose
This study (EGF20009) assessed the efficacy and tolerability of two lapatinib administration schedules as first-line monotherapy in women with ErbB2-amplified locally advanced or metastatic breast cancer.
researchgate.net
